AML, LYT-200 and PureTech

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.
PureTech announces receipt of FDA Fast Track Designation for LYT-200 in AML
PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class
PureTech Drug Gets FDA Fast-Track Designation for Leukemia
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid leukemia, as well as a separate fast-track designation for the treatment of recurrent/metastatic head and neck squamous cell carcinomas.
PureTech receives FDA fast track designation for leukemia treatment
(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia. The designation aims to expedite the development and regulatory review of drugs addressing serious conditions with unmet medical needs.
PureTech Says FDA Grants Fast Track Designation For LYT-200 In Acute Myeloid Leukemia
Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted
PharmiWeb2d
PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...
PureTech Appoints UBS as UK Corporate Broker
BOSTON, January 06, 2025 -- ( BUSINESS WIRE )-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), is pleased to announce that it has appointed UBS as its UK Corporate Broker ...
SourceSecurity22d
PureTech's RDAPSS: Autonomous perimeter surveillance
PureTech Systems Inc., a pioneer in geospatial AI-boosted video analytics for wide-area perimeter and border security, is proud to announce the launch of its Rapid Deploy Autonomous Perimeter ...
Hosted on MSN24d
PureTech sees success in Phase IIb Pulmonary Fibrosis trial
Boston-situated clinical-stage biotherapeutics company PureTech’s Phase IIb trial of deupirfenidone met all primary and secondary endpoints, slowing lung degeneration in patients with idiopathic ...
Business Wire25d
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the ...
The two doses of deupirfenidone were chosen based on PureTech’s Phase 1 data, which showed that a 550 mg TID dose of deupirfenidone provided approximately equivalent drug exposure to pirfenidone ...
Yahoo Finance29d
PureTech Systems Inc. Introduces PurifAI: The Ultimate SaaS Solution for False/Nuisance Alarm Filtering for Mass Video Monitoring Centers
PHOENIX, Dec. 12, 2024 /PRNewswire/ -- PureTech Systems Inc., a leader in geospatial AI-boosted video analytics for wide-area perimeter and border security, is excited to announce the launch of ...